On September 9, 2026, Leerink Partners initiated coverage of Nautilus Biotechnology (NASDAQCM:NAUT) with an “Outperform” recommendation. The stock closed at $0.93 on September 8, reflecting a 0.15% increase from $0.93 a week prior and a 3.09% rise from $0.90 on August 7, 2026.
As of August 28, the consensus target price for Nautilus shares stood at $4.08, indicating a potential upside of 339.70%. The current analyst recommendations include 3 “strong buy,” 4 “buy,” and 1 “hold,” with an overall positive sentiment of 87.5% as of September 1.
In its latest earnings report on July 28, Nautilus reported a revenue of $190 billion and an EPS of -0.11, surpassing the estimate of -0.1377. The company’s commitment to regulatory transparency is outlined in its EX-99.1 filing.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
